<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712983</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100G2202</org_study_id>
    <nct_id>NCT02712983</nct_id>
  </id_info>
  <brief_title>Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</brief_title>
  <acronym>iBEST-1</acronym>
  <official_title>A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University Belfast, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Antwerp, BE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan, IT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Clínic per a la Recerca Biomèdica, ES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Centrum Rotterdam, NL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital Cambridge, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton Hospital Trust, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to support the selection of a safe and tolerable tobramycin
      inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
      aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa
      colonization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or
      placebo is given in addition to the local standard care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">June 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P. aeruginosa density in sputum</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Change in P. aeruginosa bacterial load in sputum as assessed by the change in log10 colony forming units (CFUs) from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as frequency of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first use of antipseudomonal antibiotics</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by the time to first use of anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tobramycin concentration</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum tobramycin concentration</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P. aeruginosa density in sputum over the entire study duration</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Change in P. aeruginosa bacterial load in sputum from baseline as assessed by the change in colony forming units (CFUs) of P. aeruginosa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Symptom Scale Quality of Life Questionnaire for Bronchiectasis (QOL-B)</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Change from baseline on the Respiratory Symptom Scale QOL-B. Respiratory Symptoms is 1 out of 8 domains of the QOL-B instrument and is graded on a 4-point Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as rate of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as severity of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as time to onset of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring anti-pseudomonal antibiotics</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by proportion of patients requiring anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anti-pseudomonal antibiotic treatment</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by duration of use of anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Non-cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>TIP dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP dose regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Male and female patients of ≥ 18 years of age at screening (Visit 1).

          -  Proven diagnosis of non-CF BE as documented by computed tomography or high-resolution
             computed tomography

          -  At least 2 or more exacerbations treated with oral antibiotics OR 1 or more
             exacerbation requiring intravenous antibiotic treatment within 12 months prior to
             screening.

          -  FEV1 ≥ 30% predicted at screening (Visit 1).

          -  P. aeruginosa, must be documented in a respiratory sample at least 1 time within 12
             months and also present in the expectorated sputum culture at Visit 1.

        Exclusion Criteria:

          -  Patients with a history of cystic fibrosis.

          -  Patients with a primary diagnosis of bronchial asthma.

          -  Patients with a primary diagnosis of COPD associated with at least a 20 pack year
             smoking history.

          -  Any significant medical condition that is either recently diagnosed or was not stable
             during the last 3 months, other than pulmonary exacerbations, and that in the opinion
             of the investigator makes participation in the trial against the patients' best
             interests.

          -  History of hearing loss or chronic tinnitus deemed clinically significant by the
             investigator.

          -  Patients with active pulmonary tuberculosis.

          -  Patients currently receiving treatment for nontuberculous mycobacterial (NTM)
             pulmonary disease.

          -  Patients who are regularly receiving inhaled anti-pseudomonal antibiotic (during the
             study inhaled anti-pseudomonal antibiotics are not allowed other than the study
             drug).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milan</city>
        <zip>20112</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valencia</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Penarth</city>
        <state>Cardiff</state>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>February 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled tobramycin; tobramycin inhalation powder; bronchiectasis; pulmonary Pseudomonas aeruginosa infection; dose-finding study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
